Werewolf Therapeutics, Inc.
HOWL
NASDAQ·Healthcare·Biotechnology·Mkt cap $47.0M
$0.97
▲ +2.38%
P/E
-1.32
Mkt Cap
$47.0M
52-Wk Range
$0.27–$2.38
52-Week Range
$0.27 - $2.38
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 27.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary PREDATOR Platform - Conditionally activated molecules with differentiated mechanism of action
- IP Protection - Strong patent portfolio covering INDUKINE technology and applications
- Unmet Clinical Need - Addresses limitations of conventional proinflammatory immune therapies
- Expert Leadership - Experienced management team with deep oncology and immunotherapy expertise
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Revenue decline expected
Clinical trial progression of WTX-124, WTX-330, and WTX-613 toward regulatory milestones
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+153.0% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying HOWL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
JUL 31, 2026
Reported EPS of $0.08 vs -$0.28 consensus (+128.6% surprise). Revenue of $21.0M vs $21.0M expected (0.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+128.6%
Revenue trend · last 8Q
—
—
-100%
-100%
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$21.0M
Margins · last 8Q
Gross
0.0%
Operating
34.1%
Profit
17.5%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How HOWL stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related